Rnaset2 inhibits melanocyte outgrowth possibly through interacting with shootin1

Wang, Qianqian; Wang, Xiuxiu; Yan, Le; Jiang, Min; Wu, Jiaqiang; Li, Tao; Kang, Yuli; Xiang, Leihong

doi:10.1016/j.jdermsci.2015.07.004

Cited by 6 publications

(4 citation statements)

References 17 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shootin-1, also identified here as being decreased in postoperative haze eyes, is a widespread intracellular protein that appears to function in dendritic outgrowth and cell migration. [46][47][48][49][50] It was recently uncovered in a tear proteomics screen for age-related macular degeneration-associated biomarkers, 51 although more work is needed to determine what role it might play at the ocular surface.…”

Section: Discussionmentioning

confidence: 99%

Mediators of Corneal Haze Following Implantation of Presbyopic Corneal Inlays

Fenner

Liu

Koh

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE.To identify protein mediators of corneal haze following presbyopic corneal inlay surgery.METHODS. Tears were collected from eyes with corneal haze following surgery with a shapechanging corneal inlay. Samples were subjected to quantitative proteomic analysis using iTRAQ and proteins significantly increased or decreased (1.3-fold or more) in haze eyes relative to fellow eyes were identified. Expression ratios were compared to postoperative eyes without corneal haze to identify proteins selectively increased or decreased in corneal haze eyes.RESULTS. Inlay-associated haze occurred in 35% of eyes (6 of 17). Of 1443 unique tear proteins identified, eight proteins were selectively reduced in tears from postoperative haze eyes and one protein selectively increased. Proteins reduced in haze eyes included complement 4a (level relative to nonhaze eyes 0.464, P ¼ 0.037), complement factor H (0.589, P ¼ 0.048), immunoglobulin kappa variable 2-29 (0.128, P ¼ 0.006), immunoglobulin kappa variable 2D-28 (0.612, P ¼ 0.025), immunoglobulin lambda variable 7-46 (0.482, P ¼ 0.007), S100 calcium binding protein A4 (0.614, P ¼ 0.048), Shootin-1 (0.614, P ¼ 0.048), and tissue inhibitor of metalloproteinase-1 (0.736, P ¼ 0.023). The Xaa-Pro aminopeptidase 1 was increased in haze eyes relative to nonhaze eyes (1.517, P ¼ 0.023). CONCLUSIONS.Corneal haze following corneal inlay surgery is associated with reduction in levels of known inflammatory and immune mediators. These findings represent a starting point for elucidation of pathways involved in corneal haze following synthetic inlay implantation and may enable development of targeted therapies that modulate the haze response.

show abstract

Section: Discussionmentioning

confidence: 99%

Mediators of Corneal Haze Following Implantation of Presbyopic Corneal Inlays

Fenner

Liu

Koh

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…The expression level of RNase T2 was enhanced in specimens of patients with vitiligo. The overexpression of RNase T2 can induce the stress response in primary human melanocytes and keratinocytes cultured in vitro and inhibit the growth of melanocytes (67). On the other hand, RNase T2 may act as an endogenous ligand to activate antigen-presenting cells, such as DCs, thereby initiating an immune response to melanocytes (68).…”

Section: Rnase T2 In Inflammationmentioning

confidence: 99%

RNase T2 in Inflammation and Cancer: Immunological and Biological Views

Zhao

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

The RNase T2 family consists of evolutionarily conserved endonucleases that express in many different species, including animals, plants, protozoans, bacteria, and viruses. The main biological roles of these ribonucleases are cleaving or degrading RNA substrates. They preferentially cleave single-stranded RNA molecules between purine and uridine residues to generate two nucleotide fragments with 2'3'-cyclic phosphate adenosine/guanosine terminus and uridine residue, respectively. Accumulating studies have revealed that RNase T2 is critical for the pathophysiology of inflammation and cancer. In this review, we introduce the distribution, structure, and functions of RNase T2, its differential roles in inflammation and cancer, and the perspective for its research and related applications in medicine.

show abstract

“…In fact, several studies point to an oncosuppressive role for RNASET2 via monocyte/macrophage recruitment, activation and polarization ( 16 – 19 ). Somewhat surprisingly, the ribonuclease catalytic activity of RNASET2 may not be required for its oncosuppressive activity or stress mediated cell death ( ( 5 , 20 ) The efficacy of human recombinant RNASET2 in inhibiting tumor growth, cytoskeletal reorganization and inflammatory response in several disease models supports the potential for RNASET2 as a soluble therapeutic drug ( 6 , 18 , 21 , 22 ). While some of these studies have compared expression levels of RNASET2 mRNA transcript and protein in diseased tissue, studies of circulating RNASET2 protein levels are lacking.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and therapeutic potential of RNASET2 in Crohn’s disease: Disease-risk polymorphism modulates allelic-imbalance in expression and circulating protein levels and recombinant-RNASET2 attenuates pro-inflammatory cytokine secretion

et al. 2022

View full text Add to dashboard Cite

Ribonuclease T2 gene (RNASET2) variants are associated in genome wide association studies (GWAS) with risk for several autoimmune diseases, including Crohn’s disease (CD). In T cells, a functional and biological relationship exists between TNFSF15-mediated enhancement of IFN−γ production, mucosal inflammation and RNASET2. Disease risk variants are associated with decreased mRNA expression and clinical characteristics of severe CD; however, functional classifications of variants and underlying molecular mechanisms contributing to pathogenesis remain largely unknown. In this study we demonstrate that allelic imbalance of RNASET2 disease risk variant rs2149092 is associated with transcriptional and post-transcriptional mechanisms regulating transcription factor binding, promoter-transactivation and allele-specific expression. RNASET2 mRNA expression decreases in response to multiple modes of T cell activation and recovers following elimination of activator. In CD patients with severe disease necessitating surgical intervention, preoperative circulating RNASET2 protein levels were decreased compared to non-IBD subjects and rebounded post-operatively following removal of the inflamed region, with levels associated with allelic carriage. Furthermore, overexpression or treatment with recombinant RNASET2 significantly reduced IFN-γ secretion. These findings reveal that RNASET2 cis- and trans-acting variation contributed regulatory complexity and determined expression and provide a basis for linking genetic variation with CD pathobiology. These data may ultimately identify RNASET2 as an effective therapeutic target in a subset of CD patients with severe disease.

show abstract

Rnaset2 inhibits melanocyte outgrowth possibly through interacting with shootin1

Cited by 6 publications

References 17 publications

Mediators of Corneal Haze Following Implantation of Presbyopic Corneal Inlays

Mediators of Corneal Haze Following Implantation of Presbyopic Corneal Inlays

RNase T2 in Inflammation and Cancer: Immunological and Biological Views

Diagnostic and therapeutic potential of RNASET2 in Crohn’s disease: Disease-risk polymorphism modulates allelic-imbalance in expression and circulating protein levels and recombinant-RNASET2 attenuates pro-inflammatory cytokine secretion

Contact Info

Product

Resources

About